生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | Efonidipine Hydrochloride Monoethanolate, a L- and T-type dual calcium channel blocker, is suggested to have a heart rate (HR)-slowing action in addition to a blood pressure (BP)-lowering effect with IC50s of 0.35 mM and 1.8 nM for I(Ca(T)) and L-type Ca2+ channel current (I(Ca(L))), respectively[3]. In vivo research confirmed that efonidipine hydrochloride monoethanolate (40-60 mg) treatment significantly reduced the HR by 11.9% in patients with mild-to-moderate essential hypertension. Efonidipine hydrochloride monoethanolate also decreased the trough systolic and diastolic BP by 11.7 and 8.6 mmHg, respectively. Efonidipine hydrochloride monoethanolate was well-tolerated[3]. Studies showed that efonidipine hydrochloride monoethanolate prevents the sudden death and arrhythmogenicity otherwise seen in dnNRSF-Tg mice[4]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.40mL 0.28mL 0.14mL |
7.00mL 1.40mL 0.70mL |
14.00mL 2.80mL 1.40mL |
参考文献 |
---|